Screening for hyperglycaemia in pregnancy

consensus and controversy

Norman Waugh, Donald Pearson, Pamela Royle

Research output: Contribution to journalArticle

Abstract

Policy decisions on whether to implement screening programmes depend on whether the proposed programmes meet a set of criteria laid down by the World Health Organization. Screening for hyperglycaemia in pregnancy (HGP) does not meet all the criteria. However the case for screening has been strengthened by a number of recent developments, including: rising prevalence of HGP because of increasing maternal age and BMI; the results of the Hyperglycaemia and Adverse Pregnancy Outcomes study, showing that adverse effects of HGP are seen over a wider range of plasma glucose levels than previously thought; two large trials which showed the benefits of treating lesser degrees of HGP; trials showing that metformin and glibenclamide were effective and safe alternatives to immediate insulin in those without good control on lifestyle measures alone. However uncertainties remain around the threshold for treatment, and on the best screening strategy.
Original languageEnglish
Pages (from-to)553-571
Number of pages19
JournalBest Practice & Research: Clinical Endocrinology & Metabolism
Volume24
Issue number4
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Hyperglycemia
Consensus
Pregnancy
Glyburide
Metformin
Maternal Age
Pregnancy Outcome
Uncertainty
Life Style
Outcome Assessment (Health Care)
Insulin
Glucose

Keywords

  • gestational diabetes
  • hyperglycaemia in pregnancy
  • screening

Cite this

Screening for hyperglycaemia in pregnancy : consensus and controversy. / Waugh, Norman; Pearson, Donald; Royle, Pamela.

In: Best Practice & Research: Clinical Endocrinology & Metabolism, Vol. 24, No. 4, 08.2010, p. 553-571.

Research output: Contribution to journalArticle

Waugh, Norman ; Pearson, Donald ; Royle, Pamela. / Screening for hyperglycaemia in pregnancy : consensus and controversy. In: Best Practice & Research: Clinical Endocrinology & Metabolism. 2010 ; Vol. 24, No. 4. pp. 553-571.
@article{16b92c51409c431d83c3c25a7c5a7500,
title = "Screening for hyperglycaemia in pregnancy: consensus and controversy",
abstract = "Policy decisions on whether to implement screening programmes depend on whether the proposed programmes meet a set of criteria laid down by the World Health Organization. Screening for hyperglycaemia in pregnancy (HGP) does not meet all the criteria. However the case for screening has been strengthened by a number of recent developments, including: rising prevalence of HGP because of increasing maternal age and BMI; the results of the Hyperglycaemia and Adverse Pregnancy Outcomes study, showing that adverse effects of HGP are seen over a wider range of plasma glucose levels than previously thought; two large trials which showed the benefits of treating lesser degrees of HGP; trials showing that metformin and glibenclamide were effective and safe alternatives to immediate insulin in those without good control on lifestyle measures alone. However uncertainties remain around the threshold for treatment, and on the best screening strategy.",
keywords = "gestational diabetes, hyperglycaemia in pregnancy, screening",
author = "Norman Waugh and Donald Pearson and Pamela Royle",
year = "2010",
month = "8",
doi = "10.1016/j.beem.2010.06.004",
language = "English",
volume = "24",
pages = "553--571",
journal = "Best Practice & Research: Clinical Endocrinology & Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "4",

}

TY - JOUR

T1 - Screening for hyperglycaemia in pregnancy

T2 - consensus and controversy

AU - Waugh, Norman

AU - Pearson, Donald

AU - Royle, Pamela

PY - 2010/8

Y1 - 2010/8

N2 - Policy decisions on whether to implement screening programmes depend on whether the proposed programmes meet a set of criteria laid down by the World Health Organization. Screening for hyperglycaemia in pregnancy (HGP) does not meet all the criteria. However the case for screening has been strengthened by a number of recent developments, including: rising prevalence of HGP because of increasing maternal age and BMI; the results of the Hyperglycaemia and Adverse Pregnancy Outcomes study, showing that adverse effects of HGP are seen over a wider range of plasma glucose levels than previously thought; two large trials which showed the benefits of treating lesser degrees of HGP; trials showing that metformin and glibenclamide were effective and safe alternatives to immediate insulin in those without good control on lifestyle measures alone. However uncertainties remain around the threshold for treatment, and on the best screening strategy.

AB - Policy decisions on whether to implement screening programmes depend on whether the proposed programmes meet a set of criteria laid down by the World Health Organization. Screening for hyperglycaemia in pregnancy (HGP) does not meet all the criteria. However the case for screening has been strengthened by a number of recent developments, including: rising prevalence of HGP because of increasing maternal age and BMI; the results of the Hyperglycaemia and Adverse Pregnancy Outcomes study, showing that adverse effects of HGP are seen over a wider range of plasma glucose levels than previously thought; two large trials which showed the benefits of treating lesser degrees of HGP; trials showing that metformin and glibenclamide were effective and safe alternatives to immediate insulin in those without good control on lifestyle measures alone. However uncertainties remain around the threshold for treatment, and on the best screening strategy.

KW - gestational diabetes

KW - hyperglycaemia in pregnancy

KW - screening

U2 - 10.1016/j.beem.2010.06.004

DO - 10.1016/j.beem.2010.06.004

M3 - Article

VL - 24

SP - 553

EP - 571

JO - Best Practice & Research: Clinical Endocrinology & Metabolism

JF - Best Practice & Research: Clinical Endocrinology & Metabolism

SN - 1521-690X

IS - 4

ER -